Popular Articles
Today Week Month Year


The war on Hydroxychloroquine can be traced back to Gilead, the drug maker looking to profit big from Remdesivir
By Lance D Johnson // Sep 04, 2020

It was beyond strange when the major media networks began to attack a pharmaceutical, especially in the middle of a pandemic. When did the major media networks ever criticize a drug? It turns out that controversial pharmaceutical is a cheap medicine that helps human cells uptake zinc so their immune system can recover from coronavirus infections.

Brighteon.TV

Dr. Didier Raoult of France was using something as simple and cheap as hydroxychloroquine (HCQ) in combination with zinc and an antibiotic to successfully treat coronavirus patients. The news of Raoult’s success spread like wildfire, and U.S. President Donald Trump ultimately promoted the treatment, which acts as both a prophylactic and a therapeutic.

But it doesn’t matter how many doctors successfully treat coronavirus patients using HCQ and zinc. It doesn’t matter what people do in the home to help their immune system through the infection. What matters is drug company profits.

Tens of billions of dollars are on the line as Gilead tries to force dangerous Remdesivir down patient's throats

There are tens of billions of dollars on the line if doctors are able to use something as cheap as HCQ and zinc to cure patients. Gilead, the maker of Remdesivir, wants to make sure that doctors use their 5-day coronavirus treatment which costs $3,000 per patient. In comparison, a generic dose of HCQ costs anywhere between $10 and $20.

Studies on Gilead’s remdesivir are abysmal, showing adverse events for 102 (66%) of 155 remdesivir recipients. The adverse events were so horrific for remdesivir patients, that 18 (12%) of the patients had to be taken off the drug. As their drug failed, Gilead went to war with a simple treatment protocol that was working.

Gilead's desperate war against HCQ

The first hit job on HCQ came from the Veterans’ Administration hospital system study. One author of the study received numerous grants from Gilead, and in one instance, he collected nearly a quarter of a million dollars from the drug company. The flaws in the study were swiftly exposed, as Gilead tried to influence the results of the study.

The next hit job on HCQ came from Surgisphere, which published a 15,000-patient mega study that allegedly compiled data from hospitals across the world. The data, aimed at discrediting HCQ, was published in the prestigious Lancet and New England Journal of Medicine. Upon further review, the data was found to be fraudulent and the study was retracted from the journals, but it was too late: The study was used to restrict outpatient use of HCQ in the U.S. Australia, and most of Europe.

The editors of the Lancet declared Surgisphere’s scheme a “monumental fraud” but by then it was too late. These same Lancet editors had already gone out of their way to pressure the World Health Organization to suspend all trials for HCQ.

Even though France’s very own Dr. Raoult was successfully using HCQ in his treatment protocol, France was one of the first countries to severely restrict access to the drug. This suppression of treatment was done in a system of socialized medicine, which is supposed to protect patients from the abuses of pharmaceutical companies. The coordinated lobbying to suppress access to a life-saving treatment is considered a crime against humanity. Dr. Raoult fought hard against Gilead and testified against them during a meeting of the French National Assembly.

Since then, doctors around the world have followed suit and used this simple treatment protocol. A group of U.S. doctors appeared live in front of the Supreme Court to testify on the effectiveness of HCQ, but their success stories were immediately banned by Facebook, whose executives are apparently in on Gilead’s swindle. Nevertheless, the brave front line doctors are doing everything they can to get the word out to patients that there are physicians who will prescribe HCQ.

Gilead controls the panel that decides coronavirus treatment and has presidential candidate Joe Biden in their back pocket

According to the NIH, eight out of fifty-five members who are on the panel making suggestions for covid-19 treatment, are currently affiliated with Gilead. At least another twenty-four members of the panel have past associations with this domineering drug company. A drug company that is not only committing crimes against humanity, restricting access to treatments that work and pushing costly treatments that harm more people, but they also continue to control who gets access to treatment, while manipulating what kind of treatment is available and suppressing anything that could help people’s immune systems recover.

Gilead controls both political parties but has three times the financial influence over the Biden campaign, according to campaign donation records. Gilead’s top executives will be trying to save themselves from going to prison by campaigning for Joe Biden, who will gleefully carry out the plot of his handlers.

Sources include:

AmericanThinker.com

MedicineUncensored.com

PubMed.gov

AmericasFrontLineDoctorsSummit.com



Take Action:
Support NewsTarget by linking to this article from your website.
Permalink to this article:
Copy
Embed article link:
Copy
Reprinting this article:
Non-commercial use is permitted with credit to NewsTarget.com (including a clickable link).
Please contact us for more information.
Free Email Alerts
Get independent news alerts on natural cures, food lab tests, cannabis medicine, science, robotics, drones, privacy and more.

NewsTarget.com © 2022 All Rights Reserved. All content posted on this site is commentary or opinion and is protected under Free Speech. NewsTarget.com is not responsible for content written by contributing authors. The information on this site is provided for educational and entertainment purposes only. It is not intended as a substitute for professional advice of any kind. NewsTarget.com assumes no responsibility for the use or misuse of this material. Your use of this website indicates your agreement to these terms and those published on this site. All trademarks, registered trademarks and servicemarks mentioned on this site are the property of their respective owners.

This site uses cookies
News Target uses cookies to improve your experience on our site. By using this site, you agree to our privacy policy.
Learn More
Close
Get 100% real, uncensored news delivered straight to your inbox
You can unsubscribe at any time. Your email privacy is completely protected.